Refl ection and Reaction

www.thelancet.com/neurology Vol 9 September 2010 849

To submit a paper go to http://ees.elsevier.com/thelancetneurology

Alzheimer’s disease and Parkinson’s disease—a call for papers Populations are ageing, and the burden of neuro-degenerative disease is increasing. By 2030, the global burden of Parkinson’s disease is expected to have increased by 25% from 2005 levels,1 and by 2040 the number of people with dementia worldwide is expected to reach 81·1 million.2 Yet eff ective disease-modifying treatments remain elusive, not only for Alzheimer’s and Parkinson’s diseases but also for the many other neurodegenerative disorders that, although less common, can be just as devastating for the people aff ected.

The Lancet Neurology is issuing a call for papers to coincide with the 10th International Conference on Alzheimer’s and Parkinson’s diseases (AD/PD 2011), which will take place in Barcelona, Spain, March 9–13. We are particularly interested in reports of randomised controlled trials, but we also welcome high-quality original research submissions on other clinical aspects

of Alzheimer’s disease, Parkinson’s disease, and related neurodegenerative disorders. We are especially interested in papers that will be presented at the meeting, but we will also consider other submissions.

To submit a paper, please visit The Lancet Neurology’s online submission site, and indicate in your covering letter that your submission is in response to this call for papers. Manuscripts must be submitted before Dec 20, 2010, and papers that are accepted for publication will be published online to coincide with AD/PD 2011.

Heather BrownThe Lancet Neurology, London NW1 7BY, UK1 WHO. Neurological disorders: public health challenges. http://www.who.

int/mental_health/neurology/neurodiso/en/index.html (accessed July 28, 2010).

2 Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366: 2112–17.